Tocqueville Asset Management L.P. Makes New $560,000 Investment in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Tocqueville Asset Management L.P. bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,300 shares of the medical equipment provider's stock, valued at approximately $560,000.

Other institutional investors also recently made changes to their positions in the company. Cibc World Markets Corp boosted its stake in Zimmer Biomet by 13.9% in the 4th quarter. Cibc World Markets Corp now owns 31,614 shares of the medical equipment provider's stock worth $3,339,000 after buying an additional 3,854 shares during the last quarter. one8zero8 LLC purchased a new stake in Zimmer Biomet during the 4th quarter worth approximately $370,000. Natixis Advisors LLC grew its holdings in Zimmer Biomet by 12.1% during the 4th quarter. Natixis Advisors LLC now owns 71,382 shares of the medical equipment provider's stock worth $7,540,000 after acquiring an additional 7,731 shares in the last quarter. Catalyst Funds Management Pty Ltd bought a new stake in Zimmer Biomet in the fourth quarter valued at about $232,000. Finally, Brandes Investment Partners LP lifted its stake in Zimmer Biomet by 38.8% during the fourth quarter. Brandes Investment Partners LP now owns 8,118 shares of the medical equipment provider's stock worth $858,000 after purchasing an additional 2,268 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

NYSE ZBH traded up $0.58 on Monday, hitting $111.31. 1,033,989 shares of the company's stock were exchanged, compared to its average volume of 1,496,522. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90. The stock has a 50-day moving average of $106.74 and a 200-day moving average of $106.81. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The stock has a market cap of $22.16 billion, a price-to-earnings ratio of 25.01, a P/E/G ratio of 1.95 and a beta of 1.04.

Remove Ads

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the firm earned $2.20 EPS. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. Zimmer Biomet's dividend payout ratio is currently 21.57%.

Insiders Place Their Bets

In other news, SVP Lori Winkler sold 1,443 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.95% of the company's stock.

Wall Street Analysts Forecast Growth

ZBH has been the topic of several recent research reports. Barclays cut their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a research report on Monday, February 10th. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Raymond James decreased their price target on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. JMP Securities restated a "market outperform" rating and issued a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 7th. Finally, JPMorgan Chase & Co. raised shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.